JUN 10, 202655 MINS READ
High purity diisopropylamine (CAS 108-18-9, molecular formula C₆H₁₅N, molecular weight 101.19 g/mol) is a branched secondary aliphatic amine characterized by two isopropyl groups attached to a central nitrogen atom. The molecule exhibits C₂ symmetry with a nitrogen lone pair conferring strong nucleophilic and basic properties (pKa ~11.0 in aqueous solution). At ambient conditions (20–25°C), DIPA exists as a colorless to pale yellow liquid with a characteristic amine odor, displaying a boiling point of 83–84°C at 760 mmHg, melting point of −61°C, and density of approximately 0.715–0.722 g/cm³ 12. The compound demonstrates complete miscibility with most organic solvents including alcohols, ethers, hydrocarbons, and chlorinated solvents, while exhibiting limited water solubility (~1.4% w/w at 20°C) due to hydrophobic isopropyl substituents.
Critical physicochemical parameters for high purity grades include:
The high basicity and nucleophilicity of DIPA enable its function as a non-nucleophilic base in organic synthesis, a ligand precursor in organometallic catalysis, and a building block for N-alkylation reactions. However, these same properties render DIPA susceptible to oxidative degradation (forming N-oxides and imines upon air exposure), carbonyl condensation reactions with aldehydes/ketones, and acid-catalyzed decomposition, mandating rigorous storage under inert atmosphere (nitrogen or argon) in amber glass or stainless steel containers at 2–8°C 18.
The predominant industrial synthesis route involves the catalytic reductive alkylation of isopropylamine with acetone in the presence of hydrogen over supported metal catalysts. This process, exemplified in patent literature 1, employs:
The reaction mechanism proceeds via initial imine formation (isopropylamine + acetone → isopropylidene isopropylamine + H₂O), followed by heterogeneous catalytic hydrogenation of the C=N bond. The supported Pd or Pt catalysts exhibit superior activity and selectivity compared to Raney nickel or Cu-based systems, particularly in suppressing undesired aldol condensation of acetone and minimizing catalyst deactivation by water 1. Post-reaction purification involves:
While reductive alkylation dominates commercial production, alternative routes include:
Achieving pharmaceutical-grade purity (≥99.0%) necessitates multi-stage purification beyond conventional distillation:
Comprehensive quality control employs orthogonal analytical techniques:
Gas chromatography (GC-FID): Primary method for quantifying DIPA purity and identifying organic impurities. Typical conditions: DB-1 or HP-5 capillary column (30 m × 0.32 mm × 1.0 μm), split injection (1:50), oven program 40°C (5 min) → 10°C/min → 200°C (5 min), FID detection at 250°C. Retention time ~8.5 min for DIPA with baseline resolution of isopropylamine (Rt ~6.2 min), isopropanol (Rt ~4.8 min), and triisopropylamine (Rt ~12.3 min) 18
Gas chromatography-mass spectrometry (GC-MS): Structural confirmation and trace impurity identification. EI-MS fragmentation pattern: m/z 101 [M]⁺ (5%), 86 [M-CH₃]⁺ (100%, base peak), 58 [C₃H₈N]⁺ (45%), 44 [C₂H₆N]⁺ (30%) 1
Karl Fischer titration: Coulometric or volumetric determination of water content with precision ±0.01%. Specification: <0.5% for standard grade, <0.1% for anhydrous grade 12
Acid-base titration: Determination of total amine content (primary + secondary + tertiary) by titration with standardized HCl in non-aqueous medium (glacial acetic acid or isopropanol) using crystal violet indicator. Assay: 99.0–100.5% for high purity grade 1
Refractive index measurement: Rapid quality check at 20°C using Abbe refractometer. Specification: nD²⁰ = 1.392–1.394 2
¹H and ¹³C NMR spectroscopy: Structural verification and quantification of isomeric impurities. ¹H NMR (CDCl₃, 400 MHz): δ 0.96 (d, J = 6.4 Hz, 12H, CH₃), 2.96 (sept, J = 6.4 Hz, 2H, CH), 0.85 (br s, 1H, NH) 811
High purity DIPA serves as a critical building block and reagent in multiple pharmaceutical synthesis pathways:
N-Ethyl-diisopropylamine (DIPEA, Hünig's base) synthesis: DIPA undergoes reductive alkylation with acetaldehyde over Pd/Al₂O₃ catalysts (80–120°C, 10–30 bar H₂) to produce DIPEA, a widely used non-nucleophilic base in peptide coupling, protection/deprotection reactions, and API synthesis 1. The process achieves >95% yield and >99% purity when starting from high purity DIPA (>97%), as impurities like isopropylamine generate undesired N-ethyl-isopropylamine by-products that complicate purification 1. DIPEA finds extensive application in the synthesis of β-lactam antibiotics, antiviral agents (e.g., tenofovir intermediates 9), and kinase inhibitors 1415.
Fesoterodine and related muscarinic antagonists: High purity DIPA (>97%) is essential for synthesizing 3,3-diphenylpropylamine derivatives via reductive amination of 3,3-diphenylpropanal 811. Impurities in DIPA lead to formation of N-isopropyl side products and reduced chiral purity (<97% ee) of the final API, rendering it unsuitable for transdermal/transmucosal formulations 811. The purification protocol involves liberating the free base from crystalline salts using DIPA as the base, achieving >98% purity for pharmaceutical use 811.
Carbapenem antibiotics: DIPA functions as a non-nucleophilic base in the coupling of enolphosphates with thiol nucleophiles during carbapenem synthesis 10. At −15°C in N-dimethylacetamide, DIPA (1.2 equiv) promotes C-S bond formation with 92% HPLC yield, with the final product isolated as a benzyl alcohol solvate in 84% overall yield 10. The use of high purity DIPA (>98%) minimizes competing nucleophilic substitution and ensures reproducible reaction kinetics.
Kinase inhibitors and oncology drugs: DIPA serves as a base in amide coupling reactions (with HATU or EDC activators) for synthesizing pyruvate dehydrogenase kinase inhibitors 15, JAK inhibitors (filgotinib intermediates 12), and thienopyrimidine derivatives 14. Typical conditions employ 2–9 equiv DIPA in DMF or acetonitrile at 20–80°C, achieving >85% isolated yields 121415. High purity DIPA (>97%) prevents catalyst poisoning and ensures consistent reaction profiles in multi-kilogram scale-ups.
Herbicide synthesis: High purity DIPA (>95% chemical purity, >97% chiral purity for enantiomerically enriched forms) is employed in producing D-(−)-napropamide, a selective pre-emergence herbicide 357. The synthesis involves coupling α-naphthoxy propionic acid with diethylamine, where DIPA impurities reduce chiral purity below the required >97% ee specification 357. Purification via recrystallization of intermediate salts and chromatographic separation achieves the target purity for agrochemical formulations 357.
Epoxy resin curing agents: DIPA derivatives, particularly diglycidyl amine epoxy compounds, require >96% chemical purity for consistent curing kinetics and mechanical properties in aerospace composites and electronic encapsulants 6. The synthesis involves reacting DIPA with epichlorohydrin under phase-transfer catalysis, where impurities like water and isopropanol cause premature polymerization and reduce epoxy equivalent weight 6.
Boron neutron capture therapy (BNCT) agents: DIPA serves as a base in coupling reactions for synthesizing carborane-modified peptides and amino acids for cancer therapy 13. The process employs DIPA (2–5 equiv) in acetonitrile at 0–35°C to activate cyanuric chloride derivatives, achieving 68% isolated yield of protected intermediates 13. High purity DIPA (>98%) is critical to avoid competing reactions and ensure biocompatibility of the final BNCT agents.
Industrial-scale DIPA production via reductive alkylation requires careful optimization of catalyst and reactor parameters:
Key strategies for achieving high purity D
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| BASF SE | Pharmaceutical synthesis as non-nucleophilic base in peptide coupling, protection/deprotection reactions, β-lactam antibiotics, antiviral agents, and kinase inhibitor production. | N-Ethyl-diisopropylamine (DIPEA) | Achieves >95% yield and >99% purity using high purity diisopropylamine (>97%) via reductive alkylation with acetaldehyde over Pd/Al2O3 catalysts at 80-120°C and 10-30 bar H2, minimizing by-product formation even with crude feedstock containing 5-15% water and 2-10% isopropanol. |
| UNITED PHOSPHORUS LIMITED | Selective pre-emergence herbicide for agrochemical applications requiring high enantiomeric purity for optimal herbicidal activity and crop selectivity. | D-(-)-Napropamide | Produces high purity D-(-)-N,N-diethyl-2-(α-naphthoxy)propionamide with chemical purity ≥95% and chiral purity ≥97% through optimized purification protocols including recrystallization and chromatographic separation to eliminate diisopropylamine-related impurities. |
| SCHWARZ PHARMA AG (UCB PHARMA GMBH) | Muscarinic antagonist for transdermal and transmucosal drug delivery systems requiring ultra-high purity to ensure therapeutic efficacy and minimize side effects in overactive bladder treatment. | Fesoterodine | Achieves >98% purity of 3,3-diphenylpropylamine free base by liberating from crystalline salts using high purity diisopropylamine as base reagent, preventing N-isopropyl side products and maintaining >97% chiral purity essential for pharmaceutical efficacy. |
| SHIONOGI CO. LTD. | Broad-spectrum carbapenem antibiotic synthesis for treating severe bacterial infections, requiring precise control of nucleophilic substitution reactions in multi-step pharmaceutical manufacturing. | Carbapenem Antibiotics | Utilizes high purity diisopropylamine (>98%) as non-nucleophilic base at -15°C in N-dimethylacetamide for C-S bond formation in enolphosphate-thiol coupling, achieving 92% HPLC yield and 84% isolated yield with consistent reaction kinetics. |
| HANMI FINE CHEMICAL CO. LTD. | Antiviral drug intermediate production for HIV/HBV treatment, requiring stringent purity specifications to ensure safety and efficacy of final active pharmaceutical ingredients. | Tenofovir (PMPA) Intermediates | Enables production of high-purity (R)-9-[2-(phosphonomethoxy)propyl]adenine (PMPA) and tenofovir diisopropyl derivatives through optimized synthesis routes using high purity diisopropylamine, achieving pharmaceutical-grade purity for antiviral API manufacturing. |